Schedule III rescheduling under AG Order No. 6754-2026 has been treated, in much of the trade press, as the moment cannabis went federal. It did not. State-legal cannabis operators continue to operate under state authority alone; there is no federal license, no federal interstate commerce regime, and no immediate change to the FDA framework that governs Schedule III pharmaceutical products.
What does change is Section 280E of the Internal Revenue Code. Schedule III substances are not subject to 280E’s deduction prohibition. For most state-legal cannabis retailers, this is the most material near-term change — the effective tax rate on operating income drops materially once the new schedule is operative for tax purposes, and the question of timing (which tax year, which quarterly estimated payments) becomes the practical 2026 question.
The other material change is research access. Schedule III meaningfully expands the research community’s ability to acquire study-grade cannabis for clinical trials, which over a multi-year horizon has implications for the medical-use product category and for FDA-pathway product development.
What does not change: state-by-state retail operation continues to be governed by state regulators (NJ CRC, CA DCC, etc.). Banking access does not become uniform. Federal trademark registration does not open up. And CSA-derived municipal ordinance language remains operative until the underlying ordinance is amended.
The practical posture: operators should expect a tax-year question, not a regulatory transformation, in the near term.